

**PE/Cy7 anti-human CD30**

**Catalog # /** 2269590 / 100 tests  
**Size:** 2269585 / 25 tests

**Clone:** BY88

**Isotype:** Mouse IgG1,  $\kappa$

**Immunogen:** Recombinant human CD30 boosted with THP-1 cell line


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** V BP173

**Concentration:** Lot-specific



HuT-78 cells (Human T lymphoma cell line) were stained with CD30 (clone BY88) PE/Cy7 (filled histogram) or mouse IgG1  $\kappa$  PE/Cy7 isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5  $\mu$ l per million cells or 5  $\mu$ l per 100  $\mu$ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported application: in combination with IL-2 and PMA to induce T cell clone proliferation.

**Application References:**

1. Durkop H, *et al.* 1992. *Cell* 68:421.
2. Aizawa S, *et al.* 1997. *J. Biol. Chem.* 272:2042.
3. Stein H, *et al.* 1982. *Int. J. Cancer* 30:445.

**Description:** CD30, also known as Ki-1 antigen, lymphoid activation antigen CD30, and tumor necrosis factor receptor superfamily member 8 is a type I transmembrane receptor that contains four TNF receptor domains with an approximate molecular weight of 64 kD. CD30 is highly expressed on Hodgkins and Reed-Sternberg cells as well as activated, but not resting, T and B cells. CD30 has been shown to interact with a number of proteins including TRAF1, TRAF2, TRAF3, TRAF5, NPM-ALK, TRAF-interacting protein, and CD30 ligand (CD153). Signaling through CD30 is thought to limit the proliferative potential of autoreactive CD8 effector T cells and protect against autoimmunity.

**Antigen References:**

1. Durkop H, *et al.* 1992. *Cell* 68:421.
2. Aizawa S, *et al.* 1997. *J. Biol. Chem.* 272:2042.
3. Stein H, *et al.* 1982. *Int. J. Cancer* 30:445.